Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
16 Results for "
antiviral therapy
" in MedChemExpress (MCE) Product Catalog:
Products (16)
16 Results for "antiviral therapy" in MCE Product Catalog:
26
26 Publications Verification
Cat. No.: HY-17422
CAS No.: 59277-89-3
Synonyms: Aciclovir; Acycloguanosine
Acyclovir (Aciclovir) is a potent, orally active antiviral agent. Acyclovir has antiherpetic activity with IC50 values of 0.85 μM and 0.86 μM for HSV-1 and HSV-2, respectively. Acyclovir induces cell cycle perturbation and apoptosis. Acyclovir prevents bacterial infections during induction therapy for acute leukaemia .
26
26 Publications Verification
Cat. No.: HY-17422A
CAS No.: 69657-51-8
Synonyms: Aciclovir sodium; Acycloguanosine sodium
Acyclovir (Aciclovir) sodium is a potent, orally active antiviral agent. Acyclovir sodium has antiherpetic activity with IC50 values of 0.85 μM and 0.86 μM for HSV-1 and HSV-2, respectively. Acyclovir sodium induces cell cycle perturbation and apoptosis. Acyclovir sodium prevents bacterial infections during induction therapy for acute leukaemia .
2
2 Cited Publications
Cat. No.: HY-N2575
CAS No.: 77029-83-5
Cat. No.: HY-17422R
CAS No.: 59277-89-3
Synonyms: Aciclovir (Standard); Acycloguanosine (Standard)
Acyclovir (Standard) is the analytical standard of Acyclovir. This product is intended for research and analytical applications. Acyclovir (Aciclovir) is a potent, orally active antiviral agent. Acyclovir has antiherpetic activity with IC50 values of 0.85 μM and 0.86 μM for HSV-1 and HSV-2, respectively. Acyclovir induces cell cycle perturbation and apoptosis. Acyclovir prevents bacterial infections during induction therapy for acute leukaemia .
Cat. No.: HY-17422S1
CAS No.: 1185179-33-2
Synonyms: Aciclovir-d4; Acycloguanosine-d4
Cat. No.: HY-B0434G
CAS No.: 36791-04-5
Synonyms: Ribasphere (GMP); ICN-1229 (GMP)
Cat. No.: HY-P99608
CAS No.: 569658-80-6
Cat. No.: HY-17422D
CAS No.: 1628039-62-2
Synonyms: Aciclovir hydrochloride; Acycloguanosine hydrochloride
Acyclovir (Aciclovir) hydrochloride is a potent, orally active antiviral agent. Acyclovir hydrochloride has antiherpetic activity with IC50 values of 0.85 μM and 0.86 μM for HSV-1 and HSV-2, respectively. Acyclovir hydrochloride induces cell cycle perturbation and apoptosis. Acyclovir hydrochloride prevents bacterial infections during induction therapy for acute leukaemia .
Cat. No.: HY-15233G
CAS No.: 917389-32-3
Synonyms: AIC246 (GMP); MK-8228 (GMP)
Cat. No.: HY-118326
CAS No.: 1190379-37-3
MRT 68601 is a potent TBK1 inhibitor with the activity of inhibiting autophagosome formation in lung cancer cells. MRT 68601 may have potential effects against targets associated with host-dependent factors identified in SARS-CoV-2 infection. The drug targets involved in MRT 68601 are related to existing FDA-approved drugs and compounds in clinical trials, which can provide support for the development of broad-spectrum antiviral therapies .
Cat. No.: HY-N2575R
CAS No.: 77029-83-5
Cat. No.: HY-123536
CAS No.: 944278-62-0
Synonyms: A-831
AZD2836 (A-831) is a 4-aminopyrazolone compound with anti-HCV activity. AZD2836 inhibits the activity of the host cell kinase PI4KIIIα, causing metabolic disorder of the cell membrane component PI4P that is necessary for viral replication. In the HCV subgenomic replicon cell model, the EC50 values of AZD2836 for genotype 1b (Con1 strain) and genotype 1a (Lemon strain) are 270 nM and 550 nM, respectively .
Cat. No.: HY-170515A
CAS No.: 2231731-82-9
Target:
Research Areas:
(E),(Z)-RNF5 agonist 1 (Compound Analog-1) is a RNF5 agonist that can enhance the ubiquitination and degradation of SARS-CoV-2 E protein by RNF5. (E),(Z)-RNF5 agonist 1 effectively inhibits the replication of SARS-CoV-2 and significantly alleviates pulmonary pathological damage and systemic inflammatory response in mouse infection models. (E),(Z)-RNF5 agonist 1 has a strong cytotoxic effect on neuroblastoma and melanoma. (E),(Z)-RNF5 agonist 1 can be used for research on anti-cancer and anti-viral purposes .
Cat. No.: HY-L073
394 compounds
Hepatitis C virus (HCV) is a hepatotropic enveloped positive- strand RNA virus (family Flaviviridae) that infects the parenchymal cells of the liver. HCV infection is a significant public health burden. Globally, an estimated 71 million people have chronic hepatitis C virus infection. A significant number of those who are chronically infected will develop cirrhosis or liver cancer. To date, there is no vaccine against HCV, and combination pegylated alpha interferon (pIFN-) and ribavirin, the main standard-of-care treatment for HCV, is effective in only a subset of patients and is associated with a wide spectrum of toxic side effects and complications. More recently, new therapeutic approaches that target essential components of the HCV life cycle have been developed, including direct-acting antiviral (DAA) that specifically block a viral enzyme or functional protein and host-targeted agents (HTA) that block interactions between host proteins and viral components that are essential to the viral life cycle. However, the genetic diversity of HCV viruses and the stage of liver disease (i.e., cirrhosis) are revealing themselves as obstacles for effective, pan-genotypic treatments. There still exists a need for the discovery and development of new HCV inhibitors. In particular, since the future of HCV therapy will likely consist of a cocktail approach using multiple inhibitors that target different steps of infection, new antivirals targeting all steps of the viral infection cycle.
MCE offers a unique collection of 394 compounds with identified and potential anti-HCV activity. MCE Anti- Hepatitis C Virus Compound Library is a useful tool for discovery new anti-HCV drugs and other anti-infection research.
Cat. No.: HY-138794G
CAS No.: 2417089-74-6
Cat. No.: HY-L248
858 compounds
The RNA-targeted bioactive compound library is a high-quality collection of small molecules specifically designed and curated to target RNA structures and functions. It is widely applied in cutting-edge drug discovery and life science research. Unlike traditional strategies that focus on protein targets, RNA-targeted compounds can directly modulate various functional RNA molecules by influencing their splicing, translation, stability, or structural conformation, thereby enabling precise intervention in key biological processes. In the field of drug development, these compounds provide a novel approach to addressing previously “undruggable” targets and have demonstrated significant potential in areas such as oncology, antiviral therapies, and neurodegenerative diseases. For example, by targeting disease-associated RNA structural domains or regulating the aberrant expression of non-coding RNAs, these compounds can effectively inhibit disease progression or restore normal cellular function. In mechanistic studies, RNA-targeted compounds serve as valuable chemical biology tools to elucidate the roles of RNA in gene expression regulation, cellular signaling pathways, and disease development.
The MCE RNA-targeted bioactive compound library contains 858 compounds, sourced from databases such as TargetRX Atlas and R-BIND. The library features excellent structural diversity and biological activity, making it suitable for high-throughput screening (HTS), target validation, phenotypic screening, and lead compound discovery. It represents a valuable resource for RNA-related research and innovative drug development.
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
